Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Imaging, Diagnosis, Prognosis

Classification Based on the Combination of Molecular and Pathologic Predictors is Superior to Molecular Classification on Prognosis in Colorectal Carcinoma

Fangying Xu, Fenjuan Wang, Meijuan Di, Qiong Huang, Min Wang, Hu Hu, Yisen Jin, Jiankang Dong and Maode Lai
Fangying Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fenjuan Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meijuan Di
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiong Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hu Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yisen Jin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiankang Dong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maode Lai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-07-0597 Published September 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Classification based on a combination of molecular and pathologic predictors had never been done using hierarchical cluster analysis. For this purpose, we identified prognostic classification based on molecular predictors, pathologic and molecular predictors, and compared their respective prognostic efficacy together with that of tumor-node-metastasis (TNM) stage. Moreover, we investigated the prognostic significance of molecular classification in different TNM stage.

Experimental Design: Six pathologic predictors (p) and 13 immunohistochemical predictors (m) were investigated in 221 colorectal carcinomas. Unsupervised hierarchical clustering analysis was done to group the data. Survival analysis was done by Kaplan-Meier method and log-rank test, and by multivariate COX proportional hazard model.

Results: Six pathologic predictors and four molecular predictors were of significant prognostic value (P ≤ 0.05). One molecular predictor showed a trend toward significance (P = 0.085). Hierarchical clustering analysis was done based on different combinations (5p, 13m, 5m, 5p13m, and 5p5m), and distinct groups were produced except 5p (the TNM stage was excluded). Groups identified by 5m (P = 0.053) and 5p5m (P = 0.000) showed significant differences in prognosis. Groups identified by 5p5m and TNM stage were confirmed as the independent prognostic factors in a multivariate COX proportional hazard model. Moreover, groups identified by 5m could predict different prognoses in patients with stage II disease.

Conclusions: Classification based on pathologic and immunohistochemical predictors is superior to that based only on molecular predictors on prognosis. Classification based on 5m could identify additional different prognoses in patients with stage II disease.

  • colorectal carcinoma
  • prognosis
  • hierarchical cluster analysis
  • immunohistochemistry
  • molecular classification

Colorectal carcinoma is one of the leading causes of cancer mortality worldwide. Accurate prognosis analysis will greatly facilitate clinical decision of the best treatment plan and reduce the healthcare costs. Up to now, tumor-node-metastasis (TNM) staging has remained the most widely used system, but the patients operated on at the same TNM stage do not necessarily have the same prognosis. Recently, with the identification of numerous molecular predictors, a more accurate staging system is expected. There have been endeavors to build a prognostic evaluation system based on molecular markers. For example, Lyall et al. identified a prognostic immunohistochemical marker profile in 90 stage III colorectal carcinomas by unsupervised hierarchical cluster analysis of 23 markers (1). Knosel et al. evaluated 11 immunohistochemical markers in 270 colorectal carcinomas (2). However, because the pathologic and molecular predictors were always classified separately in the past (1–5), it is still unknown whether the molecular staging system would yield more accurate prognosis analyses than the traditional TNM staging system.

Unsupervised hierarchical clustering analysis is a common method to profile the gene expression or tissue microarray data. For example, it has been used in the prognostic evaluation of lung cancer and breast carcinoma (4, 5). In this study, we investigated 5 pathologic predictors and 13 immunohistochemical molecular predictors in 221colorectal carcinomas. These molecular predictors are involved in many aspects of tumor development and progression, and have prognostic significance supported by previous studies, including a tumor suppressor protein (P53), an antiapoptotic protein (Bcl2), a protein involved in tumor proliferation (Ki67), a transcription factor (nuclear factor-κB; NF-κB), an extracellular matrix receptor (syndecan-1), a cell adhesion molecule (β-catenin), a chemokine receptor (CXCR4), a nuclear hormone receptor (PPARγ), two insulin-like growth factor family proteins (IGF-IR and IGFBP7), an insulin receptor, an intracellular target of chemotherapy (thymidylate synthase), and a macrophage-specific protein (CD68).

Here, we investigated the prognostic significance of pathologic and molecular predictors, and grouped the data according to pathologic predictors, molecular predictors, and the combination of pathologic and molecular predictors by unsupervised hierarchical clustering analysis, respectively. We then evaluated and compared the prognostic significance of the TNM staging system, the molecular classification, and the pathologic-molecular classification by multivariate COX proportional hazard model. Furthermore, we identified the prognostic significance of molecular classification in different TNM stages.

Materials and Methods

Case materials. All 221 patients (66 cases died of colorectal carcinoma) with colorectal carcinoma were inhabitants of Xiaoshan District, Zhejiang Province, China. There were 121 males and 100 females. The age range of the patients was from 26 to 85 years (median, 59 years). All archival paraffin-embedded tissue blocks were collected from the Department of Pathology, Zhejiang University, and the People's No. 1 Hospital of Xiaoshan, and the Zhejiang Cancer Hospital from January 1990 to December 2000. Patient and treatment data were collected from patient records. The 221 patients had not received chemotherapy or radiotherapy prior to surgery. Pathologic predictors and immunohistochemical scores of each section were independently scored by two pathologists who were blinded to the patients' outcomes. Any interobserver divergences were resolved with a multiheaded microscope. Information about follow-ups was provided by the Xiaoshan Center of Disease Control, with a median follow-up period of 51 months (range, 1-152 months), censored to the end of 2002. This study was approved by the Ethics Committee of Biomedicine, Zhejiang University, China.

Pathology. Paraffin-embedded tissue blocks were processed according to standard histologic procedures and stained with H&E. The following pathologic predictors were derived from histology: (a) the type of histology: tubular adenocarcinoma (n = 164), papillary adenocarcinoma (n = 26), mucinous adenocarcinoma (n = 27), ring cell carcinoma, and undifferentiated carcinoma (n = 4); (b) histologic grade: low grade (n = 148; gland formation >50% in tubular adenocarcinoma and papillary carcinoma) and high grade (n = 73; gland formation <50% in tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, and undifferentiated carcinoma); (c) depth of infiltration: inside serosa (n = 199) and outside serosa (n = 22); (d) metastasis in lymph node (negative, n = 122; positive, n = 99); (e) distant metastasis (negative, n = 199; positive, n = 22); (f) TNM stages (stage I, n = 35; stage II, n = 83; stage III, n = 81; stage IV, n = 22).

Immunohistochemistry. Archival paraffin-embedded tissue blocks were consecutively cut (4 μm) and mounted on 3-aminopropyl-triethoxysilane–coated slides. Thirteen immunohistochemical predictors were investigated in this study, including P53, Bcl2, Ki67, NF-κB, syndecan-1, β-catenin, CD68, CXCR4, PPARγ, IGF-IR, IGFBP7, insulin receptor, and thymidylate synthase. Information regarding the antibodies used are summarized in Table 1 , along with the staining pattern and patient number for each marker used. Missed data were caused by a shortage of sections.

View this table:
  • View inline
  • View popup
Table 1.

Antibodies and the method of immunostaining

Immunostains by EnVision method were done according to the conditions summarized in Table 1. For negative controls, the primary antibodies were replaced with a PBS solution (100 mmol/L; pH 7.4). A definite brown granular stain was defined as positive. The percentages of positive cells were scored using the following scale: 0, no staining or <5%; 1, 5% to 25%; 2, 26% to 50%; 3, 51% to 75%; 4, >75%, except IGFBP7, Bcl2, CXCR4, and NF-κB, which were scored as 0 (<10%) or 1 (≥10%). The number of macrophages (CD68-positive cells) in the invasive margin and in the center of tumor were counted separately in four fields (40×), and mean values were calculated and then classified into two grades according to the median. Macrophage counts ranged from 0 to 164 (median, 16) in the invasive margin, and from 0 to 70 (median, 13) in the center of tumor. We noticed that the expression of CXCR4 (positive percentage or intensity) in the invasive margin of the tumor was significantly increased compared with that in the central regions of the tumor in 18.6% (34 of 183) cases, so we defined the phenomenon as CXCR4 margin.

Statistical analysis. Univariate survival analyses were done and survival curves were drawn using the Kaplan-Meier method. The differences between curves were tested by the log-rank test. Cumulative survival rate was calculated by a life-table method. Multivariate analysis was done using the COX proportional hazard model and a forward stepwise method was used to bring variables into the model. A significant difference was identified at P < 0.05, and a potential significance was identified at P < 0.1. Hierarchical cluster analyses were done by Cluster 3.0 (Stanford University), and the results were visualized by TreeView (Stanford University). Complete linkage's method was used as the cluster method, using Spearman rank correlation as an interval measure. Comparison of the resultant clusters was made by χ2 test or Fisher's exact test using SPSS 13.0 statistical software (SPSS Inc.).

Results

Univariate survival analyses of pathologic predictors and molecular predictors. Unfavorable prognosis was significantly correlated with pathologic predictors, i.e., high histologic grade, deeper infiltration, lymph node metastasis, distant metastasis, and higher TNM stage. Papillary adenocarcinoma had a better prognosis than other histologic types. Among the molecular predictors, the significant predictors included P53, IGFBP7, CD68 in the invasive margin and CXCR4 margin (Fig. 1 ), and a trend toward significant predictor was PPARγ (P = 0.085). More specifically, patients had the worst prognosis when P53 scored 2, IGFBP7 scored 0, CD68 scored 0, and CXCR4 margin scored 1, respectively. The rest of the molecular predictors, including Ki67, Bcl2, thymidylate synthase, syndecan-1, NF-κB, IGF-IR, insulin receptor, and β-catenin were not correlated with prognosis.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Survival analysis of molecular factors in colorectal carcinoma based on P53 (A), IGFBP7 (B), CXCR4 margin (C), and CD68 in the invasive margin (D).

Hierarchical clustering analysis. Unsupervised hierarchical clustering analysis was done using complete linkage method with Spearman rank test to group the data with different predictor profiles. First, we clustered data with all 13 molecular predictors (13m), two main groups (group 1, n = 50; group 2, n = 171) resulted from this process, showing no correlation with prognosis (P = 0.4238). Second, we clustered data with five molecular predictors (5m) which were significant or potentially significant in the univariate survival analyses, the resulting two groups (group 1, n = 95; group 2, n = 126) correlated with prognosis (P = 0.0532). Twenty-four patients in group 1 passed away at the census point (median survival, 61 months), and 42 patients in group 2 passed away at the census point (median survival, 45 months). Third, we clustered data with five pathologic predictors (5p), excluding TNM stage, no well-defined group was produced.

Furthermore, we combined pathologic and molecular predictors to cluster the data. Two distinct groups (group 1, n = 149; group 2, n = 72) resulted from the process of clustering 5 pathologic predictors and 13 molecular predictors (5p13m), showing no significant correlation with prognosis (P = 0.0775). Three distinct groups (group 1, n = 130; group 2, n = 67; group 3, n = 24) resulted from the process of clustering five pathologic predictors and five molecular predictors (5p5m), showing significant correlation with prognosis when comparing group 2 (median survival, 33 months) versus group 1 (median survival, 62 months; P < 0.0001) and when comparing group 3 (median survival, 38 months) versus group 1 (P = 0.0342), but there were no significant differences between groups 2 and 3 (P = 0.3918; Figs. 2 and 3 ). The 1-year, 3-year, and 5-year cumulative survival rates of group 1 were 86%, 83%, and 79%, respectively, and that of group 2 were 69%, 54%, and 47%, and that of group 3 were 75%, 61%, and 61%, respectively. We merged group 2 with group 3 in χ2 test and Fisher's exact test, and multivariate analysis.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Clustergrams of unsupervised hierarchical clustering analysis with five molecular markers (A), and five pathologic and five molecular markers (B). The gradient was scored from low (green) to high (red); black cubes, missing values. Clustered groups are identified by differently colored branches; group 1 (black), group 2 (red), and group 3 (blue).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Survival analysis of classification based on five molecular predictors (A), five pathologic and five molecular predictors (B), and five molecular predictors in TNM stage (C) by Kaplan-Meier method with log-rank test.

The efficacy of the individual clustering predictors was evaluated by χ2 test or Fisher's exact test. We found that histologic type, histologic grade, depth of infiltration, metastasis in lymph node, distant metastasis, CD68 in the invasive margin, IGFBP7, CXCR4 margin, and PPARγ showed significant differences between the two groups, whereas P53 did not show any significant difference (Table 2 ). Then we clustered the data of 5p and 4m, excluding P53, the resulting three groups showed no significant correlation with prognosis (P = 0.0919).

View this table:
  • View inline
  • View popup
Table 2.

Comparison between group 1 and groups 2 and 3 based on the characteristics of five pathologic and five molecular predictors

Furthermore, we processed Kaplan-Meier analysis in TNM stage II (n = 83) and III (n = 81), respectively, but not in TNM stage I (n = 35) and IV (n = 22) due to an insufficient numbers of patients. Cluster 5m grouped the patients of TNM stage II into two groups (group 1, n = 36; group 2, n = 48) with different survival outcomes (P = 0.0518; Fig. 3). Three patients from group 1 passed away at the census point, and 11 patients from group 2 passed away at the census point. There was a significant difference in positive rate of PPARγ (group 1,100%, 33 of 33; group 2, 43%, 20 of 47; χ2 = 28.615; P < 0.0001) rather than other molecular predictors between the two groups. Five-year cumulative survival rates were 90% and 73% for groups 1 and 2, respectively.

Multivariate analysis. Multivariate analysis was done to determine the independent prognostic significance of predictors. Age, cluster 5p5m, cluster 5m and TNM stage, histologic type, and histologic grade were analyzed by COX proportional hazard model. The results showed that only cluster 5p5m and TNM stage were independent prognostic significant markers (Table 3 ). At the first step, TNM stage was included in the model, and at the second step, cluster 5p5m was included. Other variables were excluded from the model. The relative risk of death was 1.912 (group 2 versus group 1) in classification of 5p5m. The relative risks of death were 1.449 (stage II versus stage I), 2.988 (stage III versus stage I), and 8.394 (stage IV versus stage I), respectively, according to TNM stage.

View this table:
  • View inline
  • View popup
Table 3.

Results of multivariate COX proportional hazard model

Discussion

There have been many reports published on molecular classification since the term was first introduced in 1999 (6). During the last decade, research about cancer classification had always focused on molecular predictors but ignored the robust clinical significance of pathologic predictors. In this study, we have evaluated the prognostic significance of molecular classification on 221 cases of colorectal carcinoma versus that of the TNM stage system and classification based on the combination of molecular and pathologic predictors. Hierarchical clustering analysis has been applied based on 13 molecular predictors, 5 pathologic predictors, and the combination of molecular and pathologic predictors. We found that clusters based on molecular and pathologic predictors are superior to clusters based on molecular predictors in prognosis, and molecular predictors are valuable in substaging patients with TNM stage II disease. To our knowledge, this is the first study to compare molecular predictors, pathologic predictors, and their combination in the prognostic evaluation of colorectal carcinoma.

Among the 13 molecular predictors which are involved in carcinogenesis, development, and metastasis in colorectal carcinoma, we have identified five molecular predictors which are correlated with prognosis by univariate survival analysis. To find the simplest and the most accurate classification, we clustered the data by different combinations. Defined groups were produced excluding 5p, but only cluster 5m and cluster 5p5m were significant according to prognosis by the Kaplan-Meier method. Furthermore, only cluster 5p5m was proven to be an independent factor in the COX proportional hazard model, suggesting that the combined system of pathologic and molecular predictors would perhaps be a preferred staging system, and that more molecules and more patients should be included to establish a reliable system. However, to date, the TNM stage system, including the local extent of the untreated primary tumor, the status of the regional lymph nodes and distant metastasis, is still the most valuable criterion on the prognosis of colorectal carcinoma. It is noteworthy that a sufficient number of lymph nodes and diligent search are necessary. For this reason, the American Joint Committee on Cancer has recommended the examination of at least 12 lymph nodes to diagnose patients with stage III disease (7).

There has been a heated debate on the question of adjuvant chemotherapy in patients with stage II disease (8, 9). Clinical guidelines for the management of stage II colonic cancer state that the standard care is surgical resection alone (10). However, these guidelines also point out that adjuvant chemotherapy may be considered in some cases, such as in T4. In our study, cluster 5m identified a high-risk subgroup of patients with TNM stage II disease with lower positive rates of PPARγ. PPARγ, a member of the nuclear hormone receptors, could modulate the Wnt pathway, NF-κB, cell cycle control, and expression of proapoptotic and antiapoptotic proteins. Thus, it is a potential target of adjuvant therapy in TNM stage II disease.

Among those molecular predictors, the prognostic significance of IGFBP7 is still unclear. Our study suggested that IGFBP7 positivity was associated with a better prognosis, which contradicts the study by Adachi et al. (11). Although IGFBP7 did not correlate with the macrophage in the invasive margin (data not shown), the results of cluster analysis showed that IGFBP7 was close to macrophages in the invasive margin. Macrophages play a complex role in the progression of tumors (12–16). In our study, the macrophages in the invasive margin, rather than that in the central region, were a favorable prognostic marker, and negatively correlated with either lymph node metastasis (Spearman correlation coefficient, −0.190; P = 0.006) or distant metastasis (Spearman correlation coefficient, −0.174; P = 0.011). Hence, macrophages in different regions might have different prognostic values and it is necessary to distinguish the macrophage in the invasive margin from that in the central region in future studies.

Chemokines are small chemoattractive proteins that regulate leukocyte migration and have been implicated in cancer progression and metastasis (17–19). We analyzed the correlation between CXCR4 and other pathologic and molecular predictors according to Spearman rank correlation. NF-κB could regulate cancer cells by directly up-regulating the expression of CXCR4 (20), but in our investigation, there was no correlation between CXCR4 with either NF-κB or metastasis (data not shown). Previous studies by Kato et al. indicated that tumors with focal CXCR4 staining have a higher potential for lymph node metastasis than tumors with diffuse CXCR4 staining (21), but the phenomenon of the CXCR4 margin has never been reported. Our results suggest that the CXCR4 margin, rather than CXCR4, is a predictor of worse prognosis, which is different from the results of other studies.

In conclusion, despite the number of molecular predictors which have been identified as prognostic predictors, and several molecular phenotypes which have been reported in colorectal cancer, our results indicate that molecular predictors should serve as a supplement rather than a replacement for pathologic classification. Classification based on molecular predictors could identify additional different prognoses in subtypes in stage II disease. A more accurate classification should combine pathologic and molecular predictors together.

Footnotes

  • Grant support: Bureau of Science and Technology grant (011107607), Zhejiang Province, China.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 26, 2007.
    • Received March 12, 2007.
    • Revision received May 22, 2007.

References

  1. ↵
    Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006;12:1184–91.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Knosel T, Emde A, Schluns K, et al. Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 2005;7:741–7.
    OpenUrlCrossRefPubMed
  3. Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. Ann Surg 2004;240:832–9.
    OpenUrlCrossRefPubMed
  4. ↵
    Au NHC, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101–9.
    OpenUrlCrossRefPubMed
  5. ↵
    Makretsov NA, Huntsman D, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004;10:6143–51.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–7.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Greene FL, Page DL, Fleming ID, et al. AJCC Cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
  8. ↵
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer; who benefits and by how much? J Clin Oncol 2004;22:1797–806.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Benson AB III, Schray D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II cancer. J Clin Oncol 2004;22:3408–19.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Glimelius B, Dahl O, Cedermark B, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomized trials by the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Acta Oncol 2005;44:904–12.
    OpenUrlCrossRefPubMed
  11. ↵
    Adachi Y, Itoh F, Yamamoto H, et al. Expression of angiomodulin (tumor-derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer. Int J Cancer 2001;95:216–22.
    OpenUrlCrossRefPubMed
  12. ↵
    Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000;6:3545–51.
    OpenUrlAbstract/FREE Full Text
  13. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005;115:2363–72.
    OpenUrlCrossRefPubMed
  14. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000;60:5857–61.
    OpenUrlAbstract/FREE Full Text
  15. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645–54.
    OpenUrlCrossRefPubMed
  16. ↵
    Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltration macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9:729–37.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833–9.
    OpenUrlAbstract/FREE Full Text
  18. Kim J, Mori T, Chen SL, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006;244:113–20.
    OpenUrlCrossRefPubMed
  19. ↵
    Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50–6.
    OpenUrlCrossRefPubMed
  20. ↵
    Helbig G, Christopherson KW, Jr., Bhat-Nakshatri P, et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631–8.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003;5:144–50.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 13 (17)
September 2007
Volume 13, Issue 17
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Classification Based on the Combination of Molecular and Pathologic Predictors is Superior to Molecular Classification on Prognosis in Colorectal Carcinoma
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Classification Based on the Combination of Molecular and Pathologic Predictors is Superior to Molecular Classification on Prognosis in Colorectal Carcinoma
Fangying Xu, Fenjuan Wang, Meijuan Di, Qiong Huang, Min Wang, Hu Hu, Yisen Jin, Jiankang Dong and Maode Lai
Clin Cancer Res September 1 2007 (13) (17) 5082-5088; DOI: 10.1158/1078-0432.CCR-07-0597

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Classification Based on the Combination of Molecular and Pathologic Predictors is Superior to Molecular Classification on Prognosis in Colorectal Carcinoma
Fangying Xu, Fenjuan Wang, Meijuan Di, Qiong Huang, Min Wang, Hu Hu, Yisen Jin, Jiankang Dong and Maode Lai
Clin Cancer Res September 1 2007 (13) (17) 5082-5088; DOI: 10.1158/1078-0432.CCR-07-0597
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • In vivo Fluorescence Lifetime Imaging for Monitoring the Cancer Treatment
  • Variability in Assessing Response in Metastatic Colorectal Cancer
  • 18FDG PET-MRI of Breast Tumors: Feasibility
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement